Skip to main content

Newsroom

October 12, 2023

Read now button
2023 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
July 17, 2023

Bridgebio Logo
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

PALO ALTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. Today, alongside the dedicated physicians and courageous patients who participated, the Company reports positive results from ATTRibute-CM, its Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM.

July 13, 2023

Read Now Button
2023 Summer Newsletter
Be sure to catch up on the latest happenings in our summer newsletter.
May 3, 2023

Ultromics Logo
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

| By Ultromics

Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.